Biomarin Pharmaceutical

Biomarin Pharmaceutical

Yahoo Finance • 10 days ago

The Strategic Financial Case for BioMarin Pharmaceutical (BMRN)

TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the "TCW Relative Value Mid Cap Fund". The letter can be downloaded here. Equities advanced in Q2 2026, with the S&P 500 reaching record highs... Full story

Yahoo Finance • 13 days ago

3 Healthcare Stocks That Fall Short

3 Healthcare Stocks That Fall Short Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their mo... Full story

Yahoo Finance • 23 days ago

BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone

Key Points Interested in BioMarin Pharmaceutical Inc.? Here are five stocks we like better. Amicus integration is advancing: BioMarin expects $200 million in annual non-GAAP cost savings, with most synergies realized in 2027 and full real... Full story

Yahoo Finance • 23 days ago

FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug

AstraZeneca AZN announced that the FDA accepted its regulatory filing seeking approval for its investigational enzyme replacement therapy (ERT) efzimfotase alfa to treat patients aged two years and older with hypophosphatasia (HPP). The F... Full story

Yahoo Finance • 27 days ago

BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors

SAN RAFAEL, Calif., Sept. 14, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D., Ph.D., to the company's Board of Directors, effective September 10, 2026.BioMarin... Full story

Yahoo Finance • 29 days ago

BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)'s stock rose 5% on August 31 after the company announced that it has entered into binding agreements with Ascendis Pharma A/S (NASDAQ:ASND) to resolve a global patent dispute over Ascendis's achon... Full story

Yahoo Finance • last month

Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC

Company Logo Opportunities center on earlier genetic diagnosis, targeted FGFR3 therapies, long-acting CNP analogs and oral inhibitors. Developers can improve access, affordability, adherence and lifelong complication management across the... Full story

Yahoo Finance • last month

3 Value Stocks We Think Twice About

3 Value Stocks We Think Twice About Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they're out of favor. The key risk, however, is that these stocks are u... Full story

Yahoo Finance • last month

BioMarin (BMRN) Secured 20% U.S. Royalties on Yuviwel. Is Monetizing a Rival Better than Blocking It?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has converted a global patent dispute with Ascendis Pharma A/S (NASDAQ:ASND) into a royalty-bearing license for Yuviwel, a once-weekly treatment approved to increase linear growth in children aged... Full story

Yahoo Finance • last month

Avenzo Therapeutics Announces Appointment of Barbara Bodem and Elizabeth Mily to Board of Directors as Independent Directors

SAN DIEGO, September 03, 2026--(BUSINESS WIRE)--Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the appointment of Barbara Bodem and Elizabeth Mily... Full story

Yahoo Finance • last month

4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects

Rare diseases have moved steadily from being an overlooked corner of medicine to an important frontier for drug innovation. The FDA estimates that more than 7,000 rare diseases affect more than 30 million Americans, while most of these con... Full story

Yahoo Finance • 2 months ago

Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today

Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today What Happened? Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 3.3% in the afternoon session after the company agreed to acquire Alesta Therapeutics, a clinical-... Full story

Yahoo Finance • 2 months ago

BioMarin acquiring Alesta Therapeutics for $275 million

BioMarin Pharmaceutical announced Tuesday it has entered into a definitive agreement to acquire Alesta Therapeutics for $275 million upfront, plus up to $215 million in additional payments tied to development and regulatory milestones. Th... Full story

Yahoo Finance • 2 months ago

BioMarin Pharmaceutical's Alesta Deal Strengthens Long-Term Growth Outlook, Wedbush Says

BioMarin Pharmaceutical's (BMRN) Alesta acquisition adds a new pipeline opportunity and supports long-term growth, Wedbush Securities said in a note Tuesday. The company said earlier Tuesday that it is acquiring Alesta Therapeutics for as... Full story

Yahoo Finance • 2 months ago

Does BioMarin’s Raised 2026 Outlook and ESOP Shelf Offering Reshape the Bull Case for BMRN?

Earlier this month, BioMarin Pharmaceutical reported second-quarter 2026 results showing revenue of US$989.71 million and updated earnings guidance for the second half and full year, including a slight increase in its 2026 revenue outlook... Full story

Yahoo Finance • 2 months ago

BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth

Key Points Interested in BioMarin Pharmaceutical Inc.? Here are five stocks we like better. BioMarin raised its financial outlook after second-quarter revenue approached $1 billion, lifting 2025 revenue guidance to $3.875 billion–$3.925 b... Full story

Yahoo Finance • 2 months ago

Non-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Scientific

Company Logo Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The "Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035"... Full story

Yahoo Finance • 4 months ago

2 Profitable Stocks Worth Your Attention and 1 We Find Risky

2 Profitable Stocks Worth Your Attention and 1 We Find Risky Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn't mean it will thr... Full story

Yahoo Finance • 4 months ago

BioMarin’s VOXZOGO Win In Hypochondroplasia Shapes Rare Disease Growth Story

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. BioMarin Pharmaceutical (NasdaqGS:BMRN) reported positive Phase 3 study results for VOXZOGO in children with hypochond... Full story

Yahoo Finance • 4 months ago

What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year

Key Points Krensavage bought 241,245 Ultragenyx Pharmaceutical shares last quarter. The quarter-end position value increased by $4.75 million, reflecting both trading and share price changes. The trade represented a roughly 2% increase in... Full story